ESTRO 2023 - Abstract Book

S33

Saturday 13 May

ESTRO 2023

This pooled analysis showed high efficacy of the SHARON regimen in the relief of several cancer-related symptoms. The markedly and significantly higher complete pain response rate, in patients with mild-moderate pain, suggests an earlier referral to palliative RT for patients with cancer-related pain. PD-0066 Short course radiotherapy for advanced head and neck cancer: a phase 2 study N. West 1 , M. Zarroug 1 , R. Patil 1 , J. Kovarik 1 , C. Kelly 1 , M. Jackson 1 , S. Iqbal 1 1 Newcastle upon Tyne Hospitals Trust, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom Purpose or Objective Incurable head and neck cancer has always proven difficult to manage. Patients ineligible for definitive, radical treatment are often offered palliative radiotherapy for disease and symptom control but for this cohort of patients, optimal dose fractionation remains unknown. Here we present highly conformal short course radiotherapy, 25 Gy in 5 fractions, delivered over 1 week. The objective being to evaluate whether there is opportunity to improve the therapeutic ratio for this challenging patient cohort, with comprehensive clinical follow-up and documenting progression free survival (PFS) and overall survival (OS). Materials and Methods Patients from a single academic centre with advanced HNC, unsuitable for radical treatment were offered 25 Gy in 5 daily VMAT fractions over 1 week to the gross tumour volume.

Inclusion criteria • Over 18 years of age • Disease deemed incurable • Declined definitive radical treatments • Deemed unfit for definitive radical treatment • Expected survival of >3months

Exclusion criteria • Previous radiotherapy to the region • Pregnant Data was collected to enable survival and time to tumour progression calculations as well as record the toxicity. Patient and tumour baseline characteristics are summarised in table 1.

Table 1 Patient and tumour baseline characteristics

Results Ninety-two patients (median age 71years; range 53-93years) were recruited and received the planned study dose (25Gy in 5 fractions). These patients were deemed unsuitable for radical radiotherapy because of extent of disease (59%), unfit for radical radiotherapy (35%) or the recurrence overlapped with previous radiotherapy (6%). Of these 73% had at least T4, N3, or M1 disease. Oral cavity was the most frequent subsite (29%), followed by hypopharynx (21%) and oropharynx (17%). The median overall survival and progression free survival times were 7.9 and 7.5 months respectively with 1 and 2 year survivals of 38% and 18% (figure 1). Treatments were well tolerated; no grade 4 or 5 toxicity observed and only 18% of patients demonstrating any grade 3 toxicity over the course of their follow-up.